VCNX stock forecast
Our latest prediction for Vaccinex, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 3.95$.
In the short term (2weeks), VCNX's stock price should outperform the market by 4.70%. During that period the price should oscillate between -10.53% and +18.84%.
In the medium term (3months), VCNX's stock price should underperform the market by -5.45%. During that period the price should oscillate between -44.85% and +40.67%.Get email alerts
Create a solid portfolio with VCNX
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.13$ per share.
The book value per share is -1.34$
Three months stock forecastJuly 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|